Prof. Dr. med. Leticia Quintanilla-Martinez de Fend

Senior Research Pathologist
Institute of Pathology, University Hospital & Comprehensive Cancer Center
University of Tübingen

Liebermeisterstraße 8
72076 Tübingen, Germany

Phone: +49 (0)7071 29 82979
Fax: +49 (0)7071-29-2258

Email: Leticia.Quintanilla-Fendspam prevention@med.uni-tuebingen.de

Download CV
10 most relevant publications

Professor Dr. Leticia Quintanilla de Fend, head of the Core Facility and Senior Physician at the Institute of Pathology has extensive experience in the interpretation of mouse models. From 2000 until 2008 she was a director of the mouse pathology at the Institute of Pathology of the Helmholtz Center Munich and the Pathology Screen of the German Mouse Clinic (GMC) and established various special procedures for the analysis of mouse models. Professor Quintanilla de Fend is involved in the establishment of standards in the pathology of mouse models within EU networks.

Research Interests

The main focus of my own research is the molecular pathology of malignant lymphoma. Using high throughput molecular analyses and a broad range of in vitro techniques, such as lentiviral transduction and siRNA-mediated knockdown, as well as mouse models, my aim is to better understand the genetics and biology of these complex malignancies to allow for better diagnostic classification and ultimately improve therapy and prognostic outlook for lymphoma patients. In the era of targeted therapy and individualized medicine it is required to know the genetic alterations underlying lymphomagenesis. Our current externally funded projects deal with

  1. the molecular pathology of pediatric type follicular lymphoma, a recently described entity with distinct clinical behavior,
  2. the genetic alterations in pre-clinical follicular lymphoma precursors (in situ) and the molecular events resulting in progression to manifest disease
  3. the genetic alterations of conventional t(14;18) negative follicular lymphoma
  4. the role of the transcription factor c/EBPβ and downstream targets in ALK+ anaplastic large cell lymphoma.

Other research-topics of our group, during the last years, have been EBV-associated T and NK-cell lymphoproliferations and the pathobiology of mantle cell lymphoma and peripheral T-cell lymphomas.